Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | BUB1 | O43683 | 10/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7388445 | 0.86 | NPC1 (0.50) | KMT2ANPC1RAB9A | |
| SCHEMBL7393725 | 0.83 | KDR (0.51) | KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7385161 | 0.82 | BUB1 (0.49) | KDM4EBUB1MEN1KMT2ANPC1 | |
| SCHEMBL7388529 | 0.79 | BUB1 (0.38) | KDM4EBUB1MEN1KMT2ANPC1 | |
| SCHEMBL4897236 | 0.78 | CFTR (0.49) | KDM4EBUB1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8053524 | 0.77 | ALDH1A1 (0.36) | KDM4EBUB1KMT2ANPC1RAB9A | |
| SCHEMBL6394774 | 0.76 | ROCK2 (0.42) | BUB1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL7388480 | 0.76 | NPC1 (0.34) | BUB1NPC1RAB9A | |
| SCHEMBL7360053 | 0.75 | CFTR (0.49) | KDM4EBUB1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7384289 | 0.75 | NPC1 (0.44) | KDM4EBUB1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5723462-A | SLEEP AND SEIZURE DISORDERS; COGNITION ACTIVATORS, ANXIOLYTIC AGENTS | NEUROGEN CORPORATION (US) | 1998-03-03 | — | — | US | claimed |
| US-6096887-A | USEFUL IN THE DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE DRUGS AND FOR ENHANCEMENT OF MEMORY. | NEUROGEN CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| US-5723462-A | SLEEP AND SEIZURE DISORDERS; COGNITION ACTIVATORS, ANXIOLYTIC AGENTS | NEUROGEN CORPORATION (US) | 1998-03-03 | — | — | US | disclosed |
| WO-1998002433-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1998-01-22 | — | — | WO | disclosed |